Although conventional biomarkers are still used in clinics, such as serum chromogranin, 5-HIAA and neuron-specific enolase for NET, and serum PSA for prostate cancer, these fall short when tumors with mixed cellular patterns are presented to outpatient departments. Here, KLK3 is linked to prostate carcinoma.